VB0004

VB0004 is a small molecule drug developed by Vectus Biosystems as a treatment for hypertension (high blood pressure) and fibrosis (the replacement of functional tissue by scar tissue). The compound has demonstrated potent anti-hypertensive properties and anti-fibrotic activity in the heart and kidneys. In pre-clinical trials, VB0004 has shown the ability to not only slow down the progression of fibrosis but potentially reverse the process, leading to the restoration of normal tissue architecture[1][7]. This makes it a promising candidate for treating various conditions including hypertension, heart failure, kidney failure, and pulmonary fibrosis[4][6].